US1101221083 - Common Stock
BRISTOL-MYERS SQUIBB CO
NYSE:BMY (11/22/2024, 8:26:32 PM)
After market: 58.83 -0.04 (-0.07%)58.87
+0.64 (+1.1%)
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The firm's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY 10016
P: 16092524621
CEO: Giovanni Caforio
Employees: 34100
Website: https://www.bms.com/
AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like.
Top movers analysis one hour before the close of the markets of S&P500 on 2024-11-19: top gainers and losers in today's session.
Here you can normally see the latest stock twits on BMY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: